New CEO and CSO, page-24

I agree Rogues. I was reading dr Hayes comments on his appointment in the recent announcement.

“My career has been focused on extracellular disease targets because the tools to target
intracellular proteins involved in many important diseases have not been available. I am
excited at the opportunity to join Phylogica, the industry leader in targeting these intracellular
proteins," said Dr. Hayes. "Its innovative drug delivery platform is among the most promising
in the biopharmaceutical industry. I look forward to working with Phylogica’s world-class
research scientists to apply this technology to the discovery of new drug candidates, and to
advance their lead candidates into the clinic."

This to me is awesome as it seems his interest is in the cell penetrating capabilities rather than purely the oncology side of things. With his past experience he could open a whole lot of doors that still remain un-knocked on even as yet. I think if they can do what they say re cell penetration then there should be a world of other opportunities on top of what we have seen already.